BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26875157)

  • 21. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?
    Snyder CL; Casey MJ; Lynch HT
    Womens Health (Lond); 2015 Jul; 11(4):423-7. PubMed ID: 26246179
    [No Abstract]   [Full Text] [Related]  

  • 24. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
    Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?
    Smith MJ; Gifford FL; Lalloo F; Newman WG; Evans DG
    Breast Cancer Res Treat; 2012 Jul; 134(2):895-7. PubMed ID: 22752287
    [No Abstract]   [Full Text] [Related]  

  • 30. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
    Meaney-Delman D; Bellcross CA
    Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    Yoshida R
    Breast Cancer; 2021 Nov; 28(6):1167-1180. PubMed ID: 32862296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.
    Monteiro AN; Bouwman P; Kousholt AN; Eccles DM; Millot GA; Masson JY; Schmidt MK; Sharan SK; Scully R; Wiesmüller L; Couch F; Vreeswijk MPG
    J Med Genet; 2020 Aug; 57(8):509-518. PubMed ID: 32152249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AGO Austria recommendations for genetic testing of patients with ovarian cancer.
    Marth C; Hubalek M; Petru E; Polterauer S; Reinthaller A; Schauer C; Scholl-Firon T; Singer CF; Zschocke J; Zeimet AG
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):652-4. PubMed ID: 26109557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
    Hunsinger V; Marchac AC; Derder M; Hivelin M; Lecuru F; Bats AS; Lantieri L
    Ann Chir Plast Esthet; 2016 Jun; 61(3):177-82. PubMed ID: 26946931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.